Discontinued — last reported Q3 '23
Parker-Hannifin Interest Paid remained flat by 0.0% to $96.00M in Q2 2025 compared to the prior quarter. Year-over-year, this metric declined by 21.9%, from $122.86M to $96.00M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 12.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $236.98M | $240.31M | $464.70M | $491.42M | $384.00M |
| YoY Change | — | +1.4% | +93.4% | +5.8% | -21.9% |
We use cookies for analytics. See our Privacy and Cookie Policy.